Alport syndrome is a hereditary glomerulopathy caused by a mutation in type 28 IV collagen genes, which disrupts glomerular basement membrane, leading to 29 progressive glomerulosclerosis and end-stage renal failure. There is at 30 present no cure for Alport syndrome and cell-based therapies offer promise to 31 improve renal function. Here, we found that human first trimester fetal 
3

INTRODUCTION 52 53
Alport syndrome (AS) is a genetic chronic kidney disease affecting 1 in 5,000 54 individuals. Initially, AS manifests with haematuria, proteinuria and increased 55 blood pressure, with progressive decline in renal function leading to end-stage 56 renal failure requiring replacement therapy. People with AS also suffer from 57 progressive hearing loss, anterior lenticonus, and macular flecks. AS is 58 caused by mutations in the type IV collagen genes encoding the a3/a4/a5 59 chains, which are produced exclusively by podocytes [1] . These mutations 60 affect the correct assembly of heterotrimeric ColIVa3/a4/a5 chains in the 61 glomerular basement membrane (GBM) and result in the GBM failing to 62 mature from the embryonic ColIVa1/a1/a2 type. Persistence of the immature 63
ColIVa1/a1/a2 GBM leads to its thickening and splitting, causing progressive 64 tubulointerstitial fibrosis and renal failure [1] . The only current treatment for AS 65 is blockade of the renin-angiotensin system, and proposed treatments include 66 collagen receptor blockade, anti-microRNA therapy, and stem cell therapy [2] . 67
The rationale of stem-based therapy is that stem cells isolated from healthy 68 donors will migrate and engraft in renal glomeruli, where they may 69 differentiate into functional podocytes producing new functional GBM. We 70 previously showed that human first trimester fetal blood-derived mesenchymal 71 stem cells (MSC) injected intraperitoneally into fetal mouse recipients 72 migrated to the kidneys where they engrafted in renal glomeruli [3] . However, 73
phenotype rescue by direct cell replacement is challenged by the low level of 74 donor cell engraftment and poor differentiation capacity of the donor cells [4] . 75 7 chromosomes on male samples. The cells were fully characterised as 151 previously reported [10] , showing the characteristics of stromal MSC-like cells, 152
i.e. capacity to differentiate down the osteogenic, adipogenic and 153 chondrogenic pathway, and expression of CD73, CD90 and CD105. CSC 154 were cultured for three weeks in Dulbecco's modified Eagle's medium-high 155 glucose (Invitrogen) supplemented with 10% fetal bovine serum (BioSera), 156 100 IU/mL penicillin, and 100 µg/mL streptomycin (Invitrogen), i.e. growth 157 medium (D10) on non-coated plastic dishes, or on plastic dishes coated with 158 human type IV collagen (Sigma). 
Quantitative real time RT-PCR (QRT-PCR). 207
Total RNA (n=8 mice per group) was extracted from the glomeruli using 208 confirmed by absence of amplification of mouse cDNA), and primers common 216 to both human and mouse to determine the total cDNA in each sample, as 217 previously described [12] . For both sets, the absence of dimer formation was 218 confirmed using Dissociation Curves 1.0 software (Applied Biosystems). 219
Human:mouse chimerism was estimated as a ratio. 
Blood urea analysis. 268
Blood samples were centrifuged at 1,300 g (10 min, 4°C) and the supernatant 269 was stored at -80°C until analysis. Urea was measured using a urea/ammonia 270 detection kit (R-Biopharm), according to the manufacturers instructions. All 271 samples were analysed at the same time to avoid batch variation. 272
273
Measurement of proteinuria/hematuria. 274
Urine was collected from 9 week-old mice and proteinuria was quantitatively 275 measured using mouse albumin and creatinine ELISA (albumin urinary level / 276 creatinine urinary level) (Exocell), according to the manufacturers instructions. 277 assessed for the presence of protein or erythrocytes by dipstick analysis 278 (Siemens Healthcare, Surrey, UK). Results were based on color change and 279 ranged from 0/trace to ++++, according to the manufacturer's detection guide. 280
Controls included +/+ non-transplanted mice (negative control) and -/-non-281 transplanted mice (positive control).
Analysis was performed by two 282 observers blinded as to whether each sample was from transplanted or non-283 transplanted -/-or +/+ groups. 284 285
Western Blotting. 286
Total protein was extracted using RIPAE buffer containing protease inhibitor 287 cocktail and PMSF (Sigma). Protein concentrations were determined using 288 the BCA assay (Thermo-Scientific) with BSA as standard. Proteins were run 289 on 8% SDS-PAGE, transferred to nitrocellulose membranes, blocked with milk 290 and incubated with primary antibodies for human-specific COLIVa3 (160-190 291 kDa), PODOCIN (42 kDa, Santa Cruz) and CD2AP (71 kDa, Millipore). 292
Membranes were incubated with secondary HRP-conjugated anti-goat IgG 293 (Santa Cruz) and proteins detected using enhanced chemiluminescence 294 (Thermo-Scientific). GAPDH was used as a loading control (Millipore). 
protein. 342
We injected 10 6 CSC intraperitoneally into 7 week old -/-and +/+ mice and 343 assessed the fate of donor cells 2 weeks later. CSC injection was performed 344 at 7 weeks postnatally because analysis of the disease history in -/-mice 345 revealed the presence of blood and protein in urine at this age, whereas the 346 levels of blood urea, which is a robust measure of renal function in mice, was 347 still comparable to the values found in +/+ mice. Donor cell engraftment in 348 isolated glomeruli was determined by QRT-PCR using human-specific and 349 non-specific primers for the housekeeping gene b-actin, as previously 350 described 13 . Results showed that transplanted CSC homed to glomeruli, with 351 10.8 fold higher engraftment in -/-(n=8) compared to +/+ glomeruli (n=8) 352 (Figure 2A) . Using human-specific antibody agains vimentin protein, (Figure 2D and 2E) . 362
363
Improvement of the -/-phenotype. 364
Non-transplanted -/-mice (n=25) progressively lost weight between 7 and 10 365 weeks. By 9 weeks of age, 63% mice dropped their weight below the 20% 366 endpoint level mandated by the British Home Office and had to be culled. In 367 contrast, all CSC-transplanted -/-mice (n=48) maintained their weight until 9 368 weeks ( Figure 3A) , at which age both transplanted -/-males and females 369 were heavier than age-and sex-matched non-transplanted -/-mice, with their 370 weight being similar to wild-type +/+ mice ( Figure 3B) . 371 progressively lose weight and do not survive beyond 10 weeks of age, the 441 survival time of homozygous mutant mice is extended to about 14 weeks of 442 age in mice maintained on a mixed genetic background or to 25-30 weeks on 443 the C57BL/6j background. Consequently, we suggest that the elevated blood 444 urea and 20% weight loss we report may be considered as surrogates for 445 end-stage renal failure. We found that proteinuria, which was already elevated 446 at the time of cell injection, did not return to normal levels but did not increase 447 further in transplanted -/-mice, whilst it increased in non-transplanted -/-mice 448 . This was not surprising, since structural damage to the GBM would be 449 unlikely to be reversed within 2 weeks. 
